Recursion Pharmaceuticals Files 8-K

TL;DR

RXRX filed an 8-K, check for updates.

AI Summary

Recursion Pharmaceuticals, Inc. filed an 8-K on December 17, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about new events or financial figures but serves as a notification of these sections being included. The company is incorporated in Delaware and headquartered in Salt Lake City, UT.

Why It Matters

This 8-K filing indicates that Recursion Pharmaceuticals, Inc. has submitted required disclosures to the SEC, which may contain updates or information relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure without immediate material financial or operational news.

Key Players & Entities

• RECURSION PHARMACEUTICALS, INC. (company) — Registrant
• December 17, 2024 (date) — Date of earliest event reported
• 41 S Rio Grande Street (location) — Principal executive offices address
• Salt Lake City, UT 84101 (location) — Principal executive offices city, state, zip

FAQ

Key Financial Figures

• $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar

Filing Documents

• rxrx-20241217.htm (8-K) — 23KB
• exhibit51-rxrxxopiniontemp.htm (EX-5.1) — 12KB
• image_1.jpg (GRAPHIC) — 69KB
• 0001601830-24-000245.txt ( ) — 262KB
• rxrx-20241217.xsd (EX-101.SCH) — 2KB
• rxrx-20241217_def.xml (EX-101.DEF) — 3KB
• rxrx-20241217_lab.xml (EX-101.LAB) — 23KB
• rxrx-20241217_pre.xml (EX-101.PRE) — 14KB
• rxrx-20241217_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On December 17, 2024, Recursion Pharmaceuticals, Inc. ("Recursion") filed a prospectus supplement dated December 17, 2024 (the "Prospectus Supplement") and an accompanying base prospectus, which are part of Recursion's automatic "shelf" Registration Statement on Form S-3ASR (File No. 333-264845), and which was previously filed on May 10, 2022 with the Securities and Exchange Commission (the "SEC"). The Prospectus Supplement was filed to register for resale 3,498,393 shares of Recursion's Class A common stock (the "Resale Shares") that were issued to Tempus Labs, Inc. ("Tempus") in payment for the 2024 annual license fee under the terms of that certain Master Agreement entered into by and between Recursion and Tempus as further described in Recursion's Current Report on Form 8-K filed with the SEC on November 9, 2023, which is incorporated herein by reference. The offering of the Resale Shares was made pursuant to an exemption from registration under the Securities Act of 1933, as amended. A copy of the opinion of Wilson Sonsini Goodrich & Rosati, P.C. relating to the legality of the Resale Shares is filed herewith as Exhibit 5.1.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, P.C. 23.1 Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 ). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Nathan Hatfield Nathan Hatfield Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR